{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-058082","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.366554+00:00","generated_at":"2026-06-02T16:06:24.978415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cryoport Q1 revenue falls 13% to $54.6M; net loss widens to $18.9M, adjusted EBITDA negative $7.7M","bullets":["Life Sciences Products revenue dropped 34% YoY to $17.8M, driven by slowdown in MVE cryogenic systems demand.","Life Sciences Services revenue rose 3% to $36.8M; BioStorage/BioServices up 9%.","Net loss attributable to common stockholders was $20.9M ($0.43 per share) vs $7.6M ($0.16) a year ago.","Full-year 2024 revenue guidance reaffirmed at $242-252M; CEO cites cost-reduction initiatives including workforce cuts.","Cryoport now supports 15 commercial cell & gene therapies; 675 global clinical trials as of March 31, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-058082","json":"https://secwatch.observer/filing/0001104659-24-058082.json","markdown":"https://secwatch.observer/filing/0001104659-24-058082.md","text":"https://secwatch.observer/filing/0001104659-24-058082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/0001104659-24-058082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/tm2413756d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:06:24.978415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"47c7e152204722a1405d06837baf557e2302bfef","claim":"Cryoport, Inc. reported the first quarter ended March 31, 2024 results: revenue $54.6 million, net income $0.43 per share, EPS $0.43 per share. Guidance reaffirmed.","evidence_excerpt":"filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 tm2413756d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports First Quarter 2024 Financial Results § Q1 2024 revenue of $54.6 million § 9% year-over-year increase in Commercial Cell & Gene Therapy revenue § 9% year-over-year increase in BioStorage/BioServices revenue § A total of 675 global clinical trials","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1124524/000110465924058082/0001104659-24-058082-index.htm","confidence":0.99,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$54.6 million"},{"label":"Net income","value":"$0.43 per share"},{"label":"EPS","value":"$0.43 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}